

REFERENCES

1. Hormazábal-Aguayo I, Ezzatvar Y, Huerta-Urbe N, Ramírez-Vélez R, Izquierdo M, García-Hermoso A. Incidence of type 1 diabetes mellitus in children and adolescents under 20 years of age across 55 countries from 2000 to 2022: A systematic review with meta-analysis. *Diabetes Metab Res Rev.* 2024;40:1–9.
2. Mayer-Davis EJ, Kahkoska AR, Jefferies C, Dabelea D, Balde N, Gong CX, *et al.* ISPAD Clinical Practice Consensus Guidelines 2018: Definition, epidemiology, and classification of diabetes in children and adolescents. *Pediatr Diabetes.* 2018;19:7–19.
3. Pulungan AB, Fadiana G, Annisa D. Type 1 diabetes mellitus in children: Experience in Indonesia. *Clin Pediatr Endocrinol.* 2021;30:11–8.
4. Felner EI, Klitz W, Ham M, Lazaro AM, Stastny P, Dupont B, *et al.* Genetic interaction among three genomic regions creates distinct contributions to early- and late-onset type 1 diabetes mellitus. *Pediatr Diabetes* [Internet]. 2005;6:213–20.
5. Orban T, Sosenko JM, Cuthbertson D, Krischer JP, Skyler JS, Jackson R, *et al.* Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1. *Diabetes Care* [Internet]. 2009;32:2269–74.
6. Iqbal S, Jayyab AA, Alrashdi AM, Shujauddin S, Clua-Espuny JL, Reverté-Villarroya S. The Predictive Potential of C-Peptide in Differentiating Type 1 Diabetes From Type 2 Diabetes in an Outpatient Population in Abu Dhabi. *Clin Ther.* 2024;46:696–701.
7. Kawasaki E, Oikawa Y, Okada A, Kanatsuna N, Kawamura T, Kikuchi T, *et al.* Different interaction of onset age and duration of type 1 diabetes on the dynamics of autoantibodies to insulinoma-associated antigen-2 and zinc transporter 8. Vol. 12, *Journal of Diabetes Investigation.* 2021. p. 510–5.
8. Danne T, Phillip M, Buckingham B, Jarosz-chobot P, Urakami T, Battelino T, *et al.* ISPAD Clinical Practice Consensus Guidelines 2018 Compendium. 2018;
9. DiMeglio LA, Acerini CL, Codner E, Craig ME, Hofer SE, Pillay K, *et al.* ISPAD Clinical Practice Consensus Guidelines 2018: Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. *Pediatr Diabetes.* 2018;19:105–14.
10. Smart CE, Annan F, Higgins LA, Jelleryd E, Lopez M, Acerini CL. ISPAD Clinical Practice Consensus Guidelines 2018: Nutritional management in children and adolescents with diabetes. *Pediatr Diabetes.* 2018;19:136–54.
11. Khadilkar A, Oza C. Glycaemic Control in Youth and Young Adults: Challenges and Solutions. *Diabetes, Metab Syndr Obes Targets Ther.* 2022;Volume 15:121–9.
12. Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, *et al.* Physical Activity/Exercise and Diabetes: A Position Statement of the



- American Diabetes Association. *Diabetes Care*. 2016;39:2065–79.
13. Chowdhury S. Puberty and type 1 diabetes. *Indian J Endocrinol Metab*. 2015;19:51.
 14. Papapetrou I, Swiecicka A. The impact of COVID-19 pandemic on the incidence, presentation, and management of type 1 diabetes in children and adolescents: a narrative review. *Hormones*. 2025.
 15. Zined R, Sharma R, Das S, Sharma R. Physical activity during COVID-19 pandemic and its impact on glycemic control in children with type 1 diabetes mellitus. *Int J Contemp Pediatr*. 2023;10:498–505.
 16. Bjornstad P, Dart A, Donaghue KC, Dost A, Feldman EL, Tan GS, *et al*. ISPAD Clinical Practice Consensus Guidelines 2022: Microvascular and macrovascular complications in children and adolescents with diabetes. *Pediatr Diabetes*. 2022;23:1432–50.
 17. Taplin C, Barker J. Autoantibodies in type 1 diabetes. *Autoimmunity*. 2008;41:11–8.
 18. Mohan P. M, Ramesh TC. Multiple autoimmune syndrome. *Indian J Dermatol Venereol Leprol*. 2003;69:298–9.
 19. Anaya JM, Beltrán S. The autoimmune tautology revisited. *J Transl Autoimmun*. 2023;7.
 20. Mansukhani SA, Bothun ED, Diehl NN, Mohny BG. Incidence and Ocular Features of Pediatric Myasthenias. *Am J Ophthalmol*. 2019;200:242–9.
 21. Finnis MF, Jayawant S. Juvenile myasthenia gravis: A paediatric perspective. *Autoimmune Dis*. 2011;1.
 22. Yoganathan K, Stevenson A, Tahir A, Sadler R, Radunovic A, Malek N. Bedside and laboratory diagnostic testing in myasthenia. *J Neurol*. 2022;269:3372–84.
 23. Wiendl H, Abicht A, Chan A, Della Marina A, Hagenacker T, Hekmat K, *et al*. Guideline for the management of myasthenic syndromes. *Ther Adv Neurol Disord*. 2023;16:1–31.
 24. Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, *et al*. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. *Neurology*. 2000;55:16–23.
 25. Regnault A, Morel T, de la Loge C, Mazerolle F, Kaminski HJ, Habib AA. Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PRO. *Neurol Ther*. 2023;12:1573–90.
 26. Watanabe G, Takai Y, Nagane Y, Kubota T, Yasuda M, Akamine H, *et al*. Cutoffs on severity metrics for minimal manifestations or better status in patients with generalized myasthenia gravis. *Front Immunol*. 2024;15:1–10.
 27. Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, *et al*. International consensus guidance for management of myasthenia gravis: Executive summary. *Neurology*. 2016;87:419–25.
 28. McGrady ME, Hommel KA. Medication Adherence and Health Care Utilization in Pediatric Chronic Illness: A Systematic Review. *Pediatrics*. 2013;132:730–40.
 29. Sasidharan Pillai S, Millington K. Co-existence of Type 1 Diabetes Mellitus



- and Myasthenia Gravis: A Case Report and Review of the Literature. *AACE Clin Case Reports*. 2024;10:52–4.
30. Rosen Y, Daich J, Soliman I, Brathwaite E, Shoenfeld Y. Vitamin D and autoimmunity. *Scand J Rheumatol*. 2016;45:439–47.
 31. Wiśniewska A, Szypowska A. the Role of Vitamin D in Selected Autoimmune Diseases. *Rocz Panstw Zakl Hig / Ann Natl Inst Hyg*. 2021;72:111–21.
 32. Wangke L, Medise BE, Wirahmadi A, Sekartini R, Gunardi H, Soedjatmiko S. Mental health problems in children with chronic disease at the pediatric inpatient ward of Dr. Cipto Mangunkusumo Hospital. *Paediatr Indones* [Internet]. 2025;65:37–41.
 33. Hall CA, Donza C, McGinn S, Rimmer A, Skomial S, Todd E, *et al*. Health-Related Quality of Life in Children with Chronic Illness Compared to Parents: A Systematic Review. *Pediatr Phys Ther*. 2019;31:315–22.
 34. Bonfig W, Kapellen T, Dost A, Fritsch M, Rohrer T, Wolf J, *et al*. Growth in children and adolescents with type 1 diabetes. *J Pediatr*. 2012;160.
 35. Tan Y, Xie Q, Huang Y, Yan J, Shi J, Li M, *et al*. Long-term impact of corticosteroid therapy on adult height in juvenile myasthenia gravis patients: a retrospective multicenter cohort study. *Rare Dis Orphan Drugs J*. 2025;4.
 36. White NH. Long-term Outcomes in Youths with Diabetes Mellitus. *Pediatr Clin North Am*. 2015;62:889–909.
 37. Choi IH, Yeom SW, Kim SY, You J, Kim JS, Kim M. Analysis of Cause-of-Death Mortality in Children and Young Adults with Diabetes: A Nationwide 10-Year Follow-Up Cohort Study. *Children*. 2023;10.
 38. Lin Y, Kuang Q, Li H, Liang B, Lu J, Jiang Q, *et al*. Outcome and clinical features in juvenile myasthenia gravis: A systematic review and meta-analysis. *Front Neurol*. 2023;14.